As the S&P 500 hovers near record highs and Treasury yields drop following recent retail sales data, U.S. markets continue to capture investor attention with a mix of optimism and caution. In this ...

Recent studies suggest a majority of mergers fail. Two tenured professors identified the potential pitfalls and keys to ...

Kraft Heinz struggles with market share and profit decline and yet the new plan for a turnaround sounds similar to the old ...

Ashok Leyland's Ebitda margin expanded 80 basis points (bps) to 12.8 per cent in Q3FY25, up from 12 per cent in Q3FY24, ...

After Honda backed out of merger talks, Nissan faces a critical juncture. Could tech giant Foxconn or private equity firm KKR be the lifeline it needs?

Good morning! It’s Wednesday, February 12, 2025, and this is The Morning Shift, your daily roundup of the top automotive ...

Activist investor Elliott Management has built a near 5% stake in BP and is pushing the oil company to take radical action to ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. The generic ...

The FTC argued that the merger ... market was fatal to the request for a preliminary injunction. Nonetheless, the court proceeded to analyze the transaction’s competitive effects. B. Court’s ...

Consensus estimates have the Leicestershire-based housebuilder making adjusted pre-tax profits of between £506million and ...

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. The generic pharmaceutical ...

But the mega-merger may well damage the image of the industry further – capping off a year beset with controversies over price (Turing Pharma) and allegations of market manipulation (Valeant).